sfsehut

 Ahmed glaucoma valve (AGV) is the most commonly used valve-based drainage device while Molteno, Baerveldt, Shocket, and Eagle Vision implants are the non-valved drainage devices available in the market. Therefore, novel treatment options are required to be introduced for providing relief to such patients.com/insight/request-sample/71Refractory Glaucoma Treatment OptionsThe global refractory glaucoma treatment market can be characterized based on the treatment options and devices available in the market.Globally, Glaucoma is on rise.S.com/ongoing-insight/toc/71Glaucoma drainage devices are frequently used in refractory glaucoma to reduce the intra-ocular pressure (IOC).Clinical trials of Xen System showed positive results with 44% reduction in eye pressure and 65% reduction in IOP medications in one year period. Reducing intra-ocular pressure is the most important long term medical need of refractory glaucoma patients.

However, few patients do not get completely relieved from glaucoma even after trabeculectomy surgery.coherentmarketinsights. Around 64. The Xen gel stent form Allergan reduces IOP with a permanent implant that gas meter on off becomes flexible, allowing doctors to use IOP reduction therapies event after the Xen implantation. These devices are available in either with IOP regulating valves or without it. CyPass is a micro-invasive surgery which according to the FDA guidelines needs to be performed in combination with cataract surgery. Furthermore, according to the American Academy of Ophthalmology, the current prevalence is high in Africa, and Latin America.Future Market DynamicsAccording to the American Academy of Ophthalmology, the global prevalence of glaucoma is estimated to rise to 76 million in 2020 and 11. Nearly 10% of the glaucoma patients who receive proper treatment still experience a loss of vision. Allergan received U. The Xen system has already received CE mark and has distributed more than 10,500 stents globally. market, for refractory glaucoma treatment, in early 2017.S. This is restricting the wider acceptance among patients due to increased cost. Various studies have reflected the positive outcomes of using Ahmed Glaucoma Valve in refractory glaucoma both in pediatrics and adults.Iridex Corporation, a global provider of innovative laser systems, device and consumables in ophthalmology announced at the European Glaucoma Society held in June 2016 about the positive results of its MicroPulse P3 (MP3) device. FDA approval for Xen Gel stent in November 2016. Patients who fail to respond to medications, undergo trabeculectomy surgery.Get Free PDF Research Brochure for more Professional and Technical Insights: www.3 million people were estimated to be having glaucoma globally in 2013.

Ahmed Glaucoma Valve from New World Medical Inc.Alteate option like CyPass Micro-Stent from Transcend Medical showed impressive results in patients with primary open-angle glaucoma., is a good treatment option available since 1993 for refractory glaucoma. This device also has applications in primary open angle glaucoma unresponsive to medication, neovascular glaucoma, and congenital or infantile glaucoma. Moreover, the new surgical system is also licensed for use in Canada, Switzerland, and Turkey.Get FREE TOC : www. The company plans to launch the Xen Gel stent in the U. Therefore, this device is in very high demand and usage globally. Few detailed studies with successful outcomes could lead global acceptance of this technology in future. According to the Glaucoma research Foundation, Glaucoma is the leading cause of irreversible blindness globally. The device powered with MicroPulse laser technology showed long term benefits for patients with refractory glaucoma.